NCT01101893View on ClinicalTrials.gov

A Drug Interaction Study Evaluating GSK2248761 and Raltegravir Pharmacokinetics in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
Infection, Human Immunodeficiency Virus
Interventions
DRUG

Raltegravir

raltegravir 400mg q12h x 5 days (Reference Treatment)

DRUG

GSK2248761

GSK2248761 200mg q24h x 5 days (Reference Treatment)

DRUG

GSK2248761 + Raltegravir

GSK2248761 200mg q24h + raltegravir 400mg q12h x 5 days (Test Treatment)

Trial Locations (1)

14202

GSK Investigational Site, Buffalo

Sponsors

Lead Sponsor

ViiV Healthcare
All Listed Sponsors
lead

ViiV Healthcare

INDUSTRY

NCT01101893 - A Drug Interaction Study Evaluating GSK2248761 and Raltegravir Pharmacokinetics in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter